CA3249636A1 - Pharmaceutical and nutraceutical compositions with a combination of amino acids and its use in diseases characterized by lipid accumulation in tissues - Google Patents

Pharmaceutical and nutraceutical compositions with a combination of amino acids and its use in diseases characterized by lipid accumulation in tissues

Info

Publication number
CA3249636A1
CA3249636A1 CA3249636A CA3249636A CA3249636A1 CA 3249636 A1 CA3249636 A1 CA 3249636A1 CA 3249636 A CA3249636 A CA 3249636A CA 3249636 A CA3249636 A CA 3249636A CA 3249636 A1 CA3249636 A1 CA 3249636A1
Authority
CA
Canada
Prior art keywords
nutraceutical
pharmaceutically
solvate
acceptable salt
therapeutically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3249636A
Other languages
English (en)
French (fr)
Inventor
Josep Maria DEL BAS PRIOR
Xavier Escoté Miró
Sergio Quesada Vázquez
José Manuel Fernández-Real Lemos
Jordi Mayneris Perxachs
Julio Carlos Baudin Luque
Antoni CAIMARI PALOU
Francesc Puiggròs Llavinés
Ana Castells Nobau
Original Assignee
Centro de Investigación Biomédica en Red
Fundació Eurecat
Institut d'Investigació Biomèdica de Girona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro de Investigación Biomédica en Red, Fundació Eurecat, Institut d'Investigació Biomèdica de Girona filed Critical Centro de Investigación Biomédica en Red
Publication of CA3249636A1 publication Critical patent/CA3249636A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
CA3249636A 2022-04-25 2023-04-25 Pharmaceutical and nutraceutical compositions with a combination of amino acids and its use in diseases characterized by lipid accumulation in tissues Pending CA3249636A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22382390 2022-04-25
EP22382390.7 2022-04-25
PCT/EP2023/060827 WO2023208944A1 (en) 2022-04-25 2023-04-25 Pharmaceutical and nutraceutical compositions with a combination of amino acids and its use in diseases characterized by lipid accumulation in tissues

Publications (1)

Publication Number Publication Date
CA3249636A1 true CA3249636A1 (en) 2023-11-02

Family

ID=81579974

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3249636A Pending CA3249636A1 (en) 2022-04-25 2023-04-25 Pharmaceutical and nutraceutical compositions with a combination of amino acids and its use in diseases characterized by lipid accumulation in tissues

Country Status (7)

Country Link
US (1) US20250268855A1 (cg-RX-API-DMAC7.html)
EP (1) EP4514147A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025515358A (cg-RX-API-DMAC7.html)
CN (1) CN119343061A (cg-RX-API-DMAC7.html)
CA (1) CA3249636A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024013203A (cg-RX-API-DMAC7.html)
WO (1) WO2023208944A1 (cg-RX-API-DMAC7.html)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) * 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
US11246846B2 (en) * 2017-10-23 2022-02-15 Michael S. Tempesta Trisodium citrate compositions having enhanced uptake across digestive mucosa

Also Published As

Publication number Publication date
EP4514147A1 (en) 2025-03-05
CN119343061A (zh) 2025-01-21
MX2024013203A (es) 2025-02-10
JP2025515358A (ja) 2025-05-14
WO2023208944A1 (en) 2023-11-02
US20250268855A1 (en) 2025-08-28

Similar Documents

Publication Publication Date Title
Li et al. Irisin protects against LPS-stressed cardiac damage through inhibiting inflammation, apoptosis, and pyroptosis
Reggiori et al. Autophagy: more than a nonselective pathway
Yang et al. Polysaccharides from Armillariella tabescens mycelia ameliorate renal damage in type 2 diabetic mice
JP5176964B2 (ja) ジペプチジルペプチダーゼiv阻害剤
Trinidad-Calderon et al. Maize bioactive peptides: From structure to human health
JP2020007371A (ja) 抗肥満及び抗糖尿作用を有するペプチド及びその用途
US10155022B2 (en) Fat accumulation inhibitory peptide and pharmaceutical composition for preventing or treating obesity containing the same
Qi et al. Whey protein peptides PEW and LLW synergistically ameliorate hyperuricemia and modulate gut microbiota in potassium oxonate and hypoxanthine-induced hyperuricemic rats
AU2017356160A1 (en) Methods of treating liver disease
US12219938B2 (en) Mouse model of alcohol-induced liver cancer
Liu et al. Antihypertensive activities of a solid-state culture of Taiwanofungus camphoratus (Chang-Chih) in spontaneously hypertensive rats
CN117919232B (zh) 吲哚丙酸在治疗肝硬化以及免疫性肝损伤的应用
Zhang et al. Conjugated linoleic acid (CLA) reduces intestinal fatty acid uptake and chylomicron formation in HFD-fed mice associated with the inhibition of DHHC7-mediated CD36 palmitoylation and the downstream ERK pathway
You et al. Ameliorative effect of mussel-derived ACE inhibitory peptides on spontaneous hypertension rats
Ganai et al. Regression of fibrosis/cirrhosis by Glycine propionyl-l-carnitine treatment in d-Galactosamine induced chronic liver damage
Dutta et al. Plant-derived cell-penetrating microprotein α-astratide aM1 targets Akt signaling and alleviates insulin resistance
Yang et al. Intestinal GSTpi deficiency exacerbates the severity of experimental hyperlipidemic acute pancreatitis
EP4456905B1 (en) Probiotic bacterial communities for use in the treatment of a liver disease
US20250268855A1 (en) Pharmaceutical and nutraceutical compositions with a combination of amino acids and its use in diseases characterized by lipid accumulation in tissues
Zhu et al. Effects of Celastrus orbiculatus on Epithelial Mesenchymal Transition in Gastric Mucosal Epithelial Cells by Inhibiting Lgr 5 Expression from Rats with Gastric Precancerous Lesions
CN115572321B (zh) 一种酵母肽及其制备方法和应用
Nur et al. Antihypertensive Effect of Rice Bran Derived Amino Acids Through Modulation of iNOS Expression and Renal Histopathology in DOCA Salt Induced Hypertensive Rats
Kim et al. Lean metabolic dysfunction-associated steatotic disease is reversed by betulinic acid, a therapeutic triterpene from birch bark
Kang et al. The effect of gelatinized brown rice extract on type 2 diabetes mellitus via inhibition of insulin resistance mediators in HepG2 cells
Ye et al. Salvianolic acid A attenuates Angiotensin II-induced cardiac fibrosis through regulating the Txnip signaling pathway

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20241018

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20241119

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241119

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241119

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20241119

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20241121